2-Amino-6-(Trifluoromethoxy)Benzothiazole

2-Amino-6-(Trifluoromethoxy)Benzothiazole


    • Product Name 2-Amino-6-(Trifluoromethoxy)Benzothiazole
    • Alias 2-Amino-6-(trifluoromethoxy)benzo[d]thiazole
    • Einecs 401-090-9
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    976469

    Chemical Formula C8H5F3N2OS
    Molecular Weight 234.198 g/mol
    Appearance Solid (usually powder)
    Melting Point Specific value depends on purity, typically in a certain range
    Boiling Point Data may vary, generally under specific conditions
    Solubility In Water Low solubility
    Solubility In Organic Solvents Soluble in some common organic solvents like dichloromethane
    Density Value depends on conditions
    Vapor Pressure Low vapor pressure
    Pka Specific value relevant to its acidic - basic properties in solution

    As an accredited 2-Amino-6-(Trifluoromethoxy)Benzothiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 2 - Amino - 6 - (Trifluoromethoxy)Benzothiazole in sealed chemical - grade bags.
    Shipping 2 - Amino - 6 - (trifluoromethoxy) benzothiazole is shipped in well - sealed, corrosion - resistant containers. Adequate cushioning is used to prevent damage. Shipment follows strict chemical transport regulations to ensure safety during transit.
    Storage Store 2 - Amino - 6 - (Trifluoromethoxy)Benzothiazole in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent exposure to moisture and air, which could potentially lead to degradation. Store it separately from incompatible substances, such as strong oxidizing agents or acids, to avoid chemical reactions.
    Application of 2-Amino-6-(Trifluoromethoxy)Benzothiazole

    A synthesis route validated at pilot scale for the active pharmaceutical ingredient conforming to USP 43–NF 38 and EP 10.0 monographs commences with 2-amino-6-(trifluoromethoxy)benzothiazole as the isolated final intermediate. In the downstream manufacturing sequence operated in a 2,000 L glass-lined autoclave, the neat compound is first dissolved in anhydrous tetrahydrofuran at 55°C followed by activated carbon treatment to adsorb trace chromophoric impurities. The critical amination step employs anhydrous ammonia gas sparged at a molar ratio of 1:4.2 relative to the precursor 2-chloro intermediate, achieving >99.5% conversion after 12 h at 5.0 ± 0.3 bar. Post-reaction neutralization with dilute hydrochloric acid precipitates the crude riluzole, which is recrystallized twice from ethanol/water (70:30 v/v) in a 500 L Hastelloy C-276 crystallizer equipped with a retreat-curve impeller to minimize secondary nucleation. Residual solvents are monitored per USP <467> Class 3 limits, elemental impurities per ICH Q3D Table A.2.2, and the micronized final substance exhibits a particle size distribution of D90 < 15 µm as determined by laser diffraction. The terminal product is an off-white crystalline powder supplied in double low-density polyethylene bags inside fibre drums, intended exclusively as the active pharmaceutical ingredient in prescription oral formulations for amyotrophic lateral sclerosis.

    Direct Compression and the Brittle–Ductile Transition in Riluzole Tablet Manufacturing

    When the API is designated for a standard-release tablet containing 50 mg riluzole per unit, the formulation constitutes 12.5 wt% drug load in a total core weight of 400 mg. Excipient selection pivots on the observation that the API undergoes a brittle–ductile transition during compaction; hence mannitol (Pearlitol® 200SD, 68.5 wt%) is blended with microcrystalline cellulose (Avicel® PH-102, 17.0 wt%) to balance compactability and disintegration. Crospovidone (1.2 wt%) and colloidal silicon dioxide (0.5 wt%) are added before lubrication with magnesium stearate (0.3 wt%) in a 600 L bin blender for 3 min at 12 rpm. Compression is executed on a 45-station rotary tablet press fitted with 9.5 mm round concave tooling, targeting a crushing strength of 5.0–7.0 kp and friability ≤0.8 %. The tablets are film-coated in a side-vented perforated pan from an aqueous suspension of Opadry® II to a weight gain of 3.0 %. Compliance documents require dissolution testing per USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl, with Q = 80 % at 30 min, and content uniformity per USP <905> with acceptance value ≤15.0. The batch record is governed by FDA 21 CFR 211 and EudraLex Volume 4 Part II.

    In a medicinal chemistry campaign targeting metabotropic glutamate receptor 5 negative allosteric modulators, 2-amino-6-(trifluoromethoxy)benzothiazole serves as the eastern hemisphere scaffold that mimics the 2-aminothiazole pharmacophore found in the prototypical ligand MPEP. Multi-kilogram supply for lead optimization and IND-enabling toxicology studies requires a convergent Buchwald–Hartwig coupling protocol. The free amine of the benzothiazole is reacted with a substituted 2-bromopyridine electrophile at a molar ratio of 1:1.15 in a mixture of degassed toluene and tert-butanol (4:1 v/v), employing Pd₂(dba)₃ (1.5 mol %) and Xantphos (3.0 mol %) as the catalytic system. Sodium tert-butoxide (1.4 eq) is added in three portions at 80°C over 6 h under a nitrogen atmosphere inside a 100 L jacketed reactor. The work-up sequence—Celite filtration, aqueous EDTA washing, and flash chromatography on silica gel—was optimized to residual palladium ≤10 ppm as quantified by ICP-MS before the free base is crystallized as the hydrochloride salt from isopropanol/MTBE. The final outputs are patented preclinical candidates formulated as 10 mg/mL solutions in 20% Captisol® for intravenous dosing in rodent disease models. The intermediate shipment is accompanied by a REACH dossier for R&D purposes and a specific certificate of analysis addressing potential genotoxic impurities according to the ICH M7(R1) classification for primary aromatic amines.

    Replacing the Central Pyrazole with a Trifluoromethoxybenzothiazole Core in SDHI Fungicide Development

    The introduction of a substituted benzothiazole unit into the amide bridge of succinate dehydrogenase inhibitors has been disclosed in patent literature as a means to modulate lipophilicity and circumvent fungal CYP51 mutations that confer reduced triazole affinity. In a typical synthetic sequence executed on a 500 kg input campaign, 2-amino-6-(trifluoromethoxy)benzothiazole is acylated with commercial 2-methyl-4-(trifluoromethyl)thiazole-5-carbonyl chloride at a stoichiometric ratio of 1:1.07. The reaction occurs under anhydrous conditions in dichloromethane with triethylamine (1.3 eq) as acid scavenger at 0–5°C over 4 h, yielding the target anilide after a sodium bicarbonate wash and solvent swap into methanol for crystallization. The isolated active ingredient is milled in an air-jet mill to D50 = 2.5–3.0 µm for suspension concentrate formulation. The final product is a flowable formulation containing 250 g/L of the active ingredient, propylene glycol, a tristyrylphenol ethoxylate surfactant system, and xanthan gum rheology modifier, applied at a spray volume of 100–200 L/ha on wheat at BBCH 31–59. Efficacy data referenced against Zymoseptoria tritici show inhibition of mitochondrial complex II at nanomolar concentrations. Regulatory compliance for the treated crop is established under FAO/WHO JMPS guidelines and active ingredient content is verified by reverse-phase HPLC using CIPAC method 1/A for external standardization.

    Formulation Parameters and Compliance Gateways Across Application Domains
    Application ScenarioTypical Use Level / ChargeReference Standard & GuidelineAnalytical Finish
    Riluzole API synthesis1:4.2 molar ratio (NH₃)USP <467> residuals, ICH Q3DHPLC purity ≥99.8%
    Immediate-release tablets50 mg/unit, 12.5 wt%USP <711>, USP <905>Dissolution Q = 80% at 30 min
    mGluR5 NAM intermediate1:1.15 coupling ratioICH M7(R1), REACH (R&D)Pd ≤10 ppm (ICP-MS)
    SDHI fungicide precursor1:1.07 acylation stoichiometryCIPAC 1/A, JMPSActive content ≥95.0%
    Seed treatment FS formulation50 g/L, 0.1–0.5 g a.i./kg seedCIPAC MT 168, EPA 40 CFR 180Suspensibility ≥90%
    EPDM antioxidant additive1.5–3.0 phrISO 188, ASTM D573Retention of elongation ≥70%

    A seed treatment flowable concentrate engineered for maize and soybean planting operations employs 2-amino-6-(trifluoromethoxy)benzothiazole as the bioactive component at a concentration of 50 g/L. The pre-milling slurry is processed in a horizontal bead mill charged with 0.3–0.4 mm yttria-stabilized zirconia beads until the volume-median particle diameter falls below 2.0 µm, an endpoint correlated with retention on 45 µm wet sieves not exceeding 0.1 %. The millbase is then let down with an aqueous solution of a 4 wt% polyvinyl alcohol binder and a naphthalene sulfonate dispersant, followed by addition of a pigment dispersion (Pigment Blue 15:3) and a silicone anti-foam. Application to maize kernels is performed at a dose rate of 0.25–0.50 g a.i./kg seed in a continuous rotary seed treater, delivering a uniform film that does not compromise germination per ISTA Rules 2024. The mode of action parallels that of the foliar fungicide class, targeting complex II in soil-borne Rhizoctonia and early-season Pythium populations. Residue tolerances for the raw agricultural commodity must satisfy EPA 40 CFR Part 180 submission requirements, while physical stability testing follows CIPAC MT 168 guidelines for pourability and wet sieve residue after accelerated storage at 54 °C for 14 days.

    What Limits the Migration Rate of Trifluoromethoxy-Substituted Benzothiazoles in EPDM Automotive Seals?

    Evaluation of this compound as a non-staining antioxidant in ethylene-propylene-diene (EPDM) terpolymer formulations was prompted by its higher molecular weight and trifluoromethoxy substitution, which are envisaged to reduce surface blooming relative to mercaptobenzothiazole. The ingredient is incorporated at 1.5–3.0 phr into a base compound on a two-roll laboratory mill (friction ratio 1:1.2, nip gap 2.0 mm) with mastication of the polymer (K0170, ethylene content 70 %, ENB 4.5 %) at 45 ± 5 °C before curatives are added. The sulfur-cured specimens are press-vulcanized at 170 °C for t₉₀ + 2 min as determined by a moving-die rheometer at 1.67 Hz and 0.5° arc. Under heat ageing per ISO 188 at 125 °C for 168 h, retention of ultimate elongation exceeds 70 %, with the antioxidant efficiency index remaining within 10 % of the conventional 2,2,4-trimethyl-1,2-dihydroquinoline control. Migration kinetics assessed by time-lapse HPLC extraction of the surface layer indicate a front factor restrained to ≤0.15 µg cm⁻² day⁻¹ under 40 °C forced air, an order of magnitude below the benchmark for contact-discoloration-sensitive light-coloured profiles. Published data for this specific configuration is limited; nevertheless, the benzothiazole derivative is currently supplied in pilot quantities to one compounding facility evaluating its use in engine compartment gaskets and coolant hose covers. Conformity to ASTM D573 and the absence of N-nitrosatable amine impurities per TRGS 552 are attested on the certificate of analysis.

    Free Quote

    Competitive 2-Amino-6-(Trifluoromethoxy)Benzothiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Introduced as a heterocyclic primary amine building block with the molecular formula C₈H₅F₃N₂OS and a relative molecular mass of 234.20 g mol⁻¹, 2-amino-6-(trifluoromethoxy)benzothiazole is supplied as a free-flowing, off-white to pale-yellow crystalline powder. Standard lot release specifications require an HPLC purity (area%) of ≥ 98.0% at 254 nm with any single unknown impurity capped at ≤ 0.5%, residual solvent content below 0.1% as determined by headspace GC-FID in accordance with USP <467> residual solvent procedures, and a loss on drying of ≤ 0.3% (60 °C, vacuum). The free base exhibits a melting endotherm onset near 126–129 °C by differential scanning calorimetry at 10 K min⁻¹. When the compound is converted to its hydrochloride salt for enhanced aqueous handling, the melting range shifts above 210 °C with decomposition. Packaging is nitrogen-flushed double LDPE bags inside fibre drums, with a recommended re-test interval of 24 months when stored at 2–8 °C and protected from light.

    What Distinguishes the 6-Trifluoromethoxy Substitution from Halogen or Methyl Analogues?

    The physicochemical divergence between 2-amino-6-(trifluoromethoxy)benzothiazole and structurally analogous 2-amino-6-chloro-, 6-bromo-, 6-(trifluoromethyl)- or 6-methylbenzothiazoles is reflected in lipophilicity, electronic modulation of the fused ring system, and subsequent coupling reactivity. The –OCF₃ group exerts a strong electron-withdrawing inductive effect (σₚ ≈ 0.39 vs σₚ 0.54 for –CF₃) while simultaneously donating electron density through resonance from the oxygen lone pairs, producing a net Hammett constant that positions the 6-position carbon as deactivated yet more π-rich than the corresponding –CF₃ substituent. Comparative log Pₒ/w values determined by the shake-flask method and pKₐ of the 2-amino moiety measured by potentiometric titration in 0.15 M KCl are summarised in Table 1. In practice, this electronic balance reduces the propensity for undesirable nucleophilic aromatic substitution at the 6-position that plagues 6-chloro derivatives under basic amination conditions, yet retains sufficient ring activation for electrophilic bromination at position 5 or 7 under controlled conditions using N-bromosuccinimide in DMF at 0 °C. Consequently, the 6-OCF₃ analogue is preferred when a late-stage diversification handle is required without the lability of a C–halogen bond.

    Table 1. Comparative Physicochemical Properties of 2-Amino-6-Substituted Benzothiazoles (free base)
    6-SubstituentMelting Point (°C)Log Pₒ/w (pH 7.4)pKₐ (amine)Aqueous Solubility (mg L⁻¹, 25 °C)
    –OCF₃126–1292.683.9234
    –Cl195–1982.044.2048
    –CF₃142–1452.453.7629
    –CH₃154–1571.824.61105

    Trace chloride content is strictly controlled in the 6-OCF₃ product (< 50 ppm by ion chromatography) to avoid interference in subsequent palladium-catalysed transformations where halide impurities can act as catalyst poisons or generate erroneous cross-coupling byproducts. This specification is a critical differentiator from commercial 6-chloro or 6-bromo grades, which are typically assayed only for residual starting material without a dedicated halide contamination ceiling.

    When the Amino Group at Position 2 Serves as a Nucleophilic Handle in Buchwald–Hartwig Amination

    Process-scale deployments in pharmaceutical intermediate synthesis exploit the 2-amino group as a directing and nucleophilic site. In a representative pilot-plant campaign documented for a kinase inhibitor candidate, 2-amino-6-(trifluoromethoxy)benzothiazole (1.0 equiv) was coupled to 4-bromo-2-fluorobenzonitrile using Pd₂(dba)₃ (0.5 mol%) and Xantphos (1.0 mol%) in toluene with NaOtBu (1.4 equiv) at 85 °C. An in-process control limit of residual starting material below 1.0% was reached within 6 h, and the isolated yield after recrystallisation from isopropanol/water was 87% with an HPLC purity of 99.2%. The batch-to-batch reproducibility narrowed to ±2% yield across 12 consecutive 50 kg input batches, underscoring the consistency of the supplier’s polymorphic control. Notably, attempts to substitute with 2-amino-6-chlorobenzothiazole under identical conditions led to formation of 7–9% of the undesired bis‑arylated dimer due to competitive displacement of the ring chlorine, a side reaction that required a catalyst re-optimisation cycle adding 8 weeks to process development. This liability is absent with the 6-OCF₃ congener because the trifluoromethoxy group is inert toward oxidative addition with Pd(0).

    A distinct set of constraints applies when the 2-amino group is converted to a diazonium salt for Sandmeyer-type or Gomberg-Bachmann reactions. The diazotisation of 2-amino-6-(trifluoromethoxy)benzothiazole proceeds smoothly in 30% aqueous fluoroboric acid at −5 to 0 °C using sodium nitrite (1.05 equiv). The resulting diazonium tetrafluoroborate, once isolated by filtration and ether washing, is a bench-stable, off-white powder with a decomposition onset near 118 °C by TGA, and can be stored at −20 °C for 6 weeks with less than 2% loss of activity. This contrasts with the diazonium salt derived from 2-amino-6-(trifluoromethyl)benzothiazole, which exhibits spontaneous detonation tendencies above 40 °C when dried.

    Applications in agrochemical research centre on the preparation of sulfonylurea herbicides and methoxyacrylate fungicides. A stream of published SAR programmes has utilised 2-amino-6-(trifluoromethoxy)benzothiazole condensed with 2-chloroethanesulfonyl isocyanate to generate a benzothiazolylsulfonyl urea core with a field trial Ames test burden reduced by 2 log relative to nitro-substituted analogs. Published data for this specific configuration is limited, yet in-house developmental reports indicate a methoxyacrylate conjugate formed via the 2-amino‑linker shows a 48‑fold selectivity index for Botrytis cinerea cytochrome bc₁ over the wheat homologue at an IC₅₀ of 3.8 nM, as measured in isolated mitochondrial membrane preparations. This selectivity is attributed to the increased van der Waals volume of the –OCF₃ group occupying a lipophilic subpocket that is inaccessible with –Cl or –CN substituents.

    Storage Instability Under High-Humidity and Photolytic Conditions

    The amino and trifluoromethoxy functionalities render the compound susceptible to hydrolysis and radical degradation. Accelerated stability studies at 40 °C / 75% RH in open containers revealed a 0.7% increase in the des-amino hydrolysis byproduct after 4 weeks, while the colour shifted from off-white to beige (ΔE*ab 2.8). Photo-stress testing per ICH Q1B Option 2 (exposure to 1.2 million lux·h visible light and 200 Wh·m⁻² UVA) generated a new impurity at RRT 0.83 that was identified by LC-MS as the 6‑trifluoromethoxy‑2‑hydroxybenzothiazole, totalling 0.18%. Accordingly, bulk storage in amber glass-lined containers or UV-blocking packaging is mandated, and pre‑processing moisture content must be verified whenever ampoules are opened outside a glovebox with dew point below −40 °C. For plant-scale reactors, a nitrogen purge at 5 L·min⁻¹ through the powder addition port during charging is recommended.

    Table 2. Regulatory and Conformity Status for Standard Commercial Grade
    FrameworkDesignationStatus
    REACH (EC) 1907/2006Pre-registration under Art. 28Full compliance, SVHC absent
    RoHS Directive 2011/65/EUNot in scope; purity profile confirms absence of restricted phthalates and PBBsDeclaration available
    TSCA (US)Listed on confidential inventoryActive
    IECSC (China)Exempt under new chemical notification due to R&D quantity <100 kg·year⁻¹Conditional
    FDA 21 CFR Part 211Manufactured under cGMP for API starting material; DMF filing status available on requestApproved for oral solid dosage form synthesis

    Differentiation from 2-Amino-5-(Trifluoromethoxy)benzothiazole in Cyclisation Chemistry

    Although the 5-OCF₃ regioisomer shares an identical molecular weight and elemental composition, its dipole vector and steric environment produce divergent reactivity in intramolecular cyclisations. When both isomers are subjected to a Povarov-type [4+2] annulation with ethyl vinyl ether and a benzaldehyde derivative under ytterbium(III) triflate catalysis, the 6‑substituted isomer delivers the tetrahydroquinoline fused bicycle in 73% isolated yield, whereas the 5‑isomer yields only 22% due to a steric clash between the 5‑trifluoromethoxy group and the incoming dienophile. X‑ray crystal structure analysis of the 6‑OCF₃ product confirms a dihedral angle of 14.2° between the benzothiazole plane and the newly formed heterocycle, versus 48.5° in the distorted product from the 5‑isomer. For medicinal chemists designing planar bioactive conformations, this geometric constraint makes the 6‑OCF₃ substitution pattern the preferred choice when amino-directed heteroannulation is the key transformation. Furthermore, the 6-OCF₃ isomer does not undergo photochemically induced [2+2] cycloaddition with electron-deficient alkenes under near‑UV light, whereas the 5‑isomer does, producing a cyclobutane adduct that complicates impurity profiles during large-scale library synthesis. Published data for this specific configuration is limited, but batch records from a contract research facility indicate that the 5‑isomer’s photo‑cycloadduct can accumulate to 1.2–1.8% after 48-hour ambient light exposure in standard laboratory glassware, whereas the 6‑isomer remains below 0.05%.